Clinical Director of the Plasma Cell Disorders Program, Associate Professor of Medicine
Dr. Mark’s research focus has been on development of novel therapies for the care of multiple myeloma, including stem cell collection protocols and transplantation conditioning regimens. As a clinical trialist, he has been principal investigator on phase 1 trials of new compounds for use in refractory myeloma and stem cell transplantation. He has also led phase 2 and 3 studies designed to maximize treatment efficacy in newly diagnosed and relapsed myeloma. As every myeloma is genetically distinct, his aim to develop and deliver personalized therapy for every patient based on scientific rationale.
years treating myeloma: 9
Number of Myeloma Patients Treated Annually: 200-500
Details & contact info
Anschutz Medical Campus 1665 Aurora Court MS F754
Aurora, CO, United States, 80045
Send a message to Tomer Mark, MD